# US 2012/0269854 A1 · Method of Enhancing KSHV LANA1 Immunogenicity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269854 A1
- Document ID: US20120269854A1
- Status: Published application
- Kind: A1
- Application number: 13/334,657
- Filed: 2011-12-22
- Published: 2012-10-25
- Earliest claimed: 2007-08-15
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Inventors: Yuan Chang; Patrick S. Moore
- Web page: https://patentgrep.com/patent/US20120269854A1

## CPC

- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/12: Viral antigens
- A61P 31/22: for herpes viruses
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/585: {wherein the target is cancer}
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12N 2710/16422: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16471: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein.

## Claims

### Claim 1 (depends on 23)

A method of eliciting an immune response to KSHV LANA1 in a patient comprising introducing into a cell of the patient the ieLANA1 peptide of claim 23.

### Claim at position 2

2-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1, comprising transferring a nucleic acid comprising a gene into a cell of the patient, wherein the gene encodes and expresses the ieLANA1 polypeptide.

### Claim at position 4

18-22. (canceled)

### Claim 23

An immunologically-enhanced LANA1 polypeptide (“ieLANA1 polypeptide”) for eliciting a CTL immune response to LANA1, comprising a LANA1 amino acid sequence comprising one or more LANA1 T-cell epitopes, wherein the LANA1 amino acid sequence is modified to exhibit increased CTL immune response as compared to wild-type LANA1 protein.

### Claim 24 (depends on 23)

The ieLANA1 polypeptide of claim 23, wherein the ieLANA1 polypeptide does not comprise a portion of a LANA1 central repeat domain having the capacity to inhibit proteasomal degradation of a polypeptide or inhibit translation of a polypeptide attached in frame to that portion of the LANA1 central repeat domain, so that the ieLANA1 polypeptide exhibits increased CTL immune response as compared to wild-type LANA1 protein.

### Claim 25 (depends on 24)

The ieLANA1 polypeptide of claim 24, wherein the LANA1 amino acid sequence comprises the amino acid sequence of SEQ ID NO: 1 in which a portion of the LANA1 central repeat domain CR1 is modified to decrease the ability of that portion to inhibit CTL immune response as compared to wild-type LANA1 protein.

### Claim 26 (depends on 25)

The ieLANA1 polypeptide of claim 25, wherein the LANA1 amino acid sequence comprises the amino acid sequence of SEQ ID NO: 1 in which from about amino acid 330 to about amino acid 938 are deleted.

### Claim 27

(canceled)

### Claim 28 (depends on 25)

The ieLANA1 polypeptide of claim 25, wherein a portion of CR1 of the LANA1 amino acid sequence is modified in the ieLANA1 polypeptide to decrease the ability of that portion of CR1 to inhibit CTL immunogenicity of the ieLANA1 polypeptide.

### Claim 29 (depends on 28)

The ieLANA1 polypeptide of claim 28, wherein the LANA1 amino acid sequence is modified such that CR1 is substantially or completely deleted.

### Claim 30 (depends on 28)

The ieLANA1 polypeptide of claim 28, wherein the LANA1 amino acid sequence comprises the amino acid sequence of SEQ ID NO: 1 in which from about 20 to 107 amino acids of amino acids 321-428 are deleted.

### Claim at position 13

31-34. (canceled)

### Claim 35 (depends on 23)

The ieLANA1 polypeptide of claim 23, wherein the ieLANA1 polypeptide comprises the LANA1 amino acid sequence comprising one or more LANA1 T-cell epitopes and a protein destabilization domain and the ieLANA1 polypeptide exhibits increased proteasomal degradation as compared to wild-type LANA1 protein.

### Claim 36 (depends on 35)

The ieLANA1 polypeptide of claim 35, wherein the protein destabilization domain is one of a D-Box, KEN, PEST, Cyclin A and UFD domain/substrate.

### Claim at position 16

37-38. (canceled)

### Claim 39 (depends on 23)

An isolated nucleic acid comprising an open reading frame encoding an ieLANA1 polypeptide for eliciting a CTL immune response to LANA1 as claimed in claim 23.

### Claim 40

A polypeptide other than full-length LANA1 protein, comprising at the N-terminal or C-terminal end of the polypeptide, or inserted within the polypeptide an amino acid sequence obtained from or derived from CR1 region of a LANA1 central repeat domain and having the capacity to inhibit CTL immune response as compared to the same polypeptide without the amino acid sequence.

### Claim 41 (depends on 40)

The polypeptide of claim 40, wherein the polypeptide comprises from about amino acid 330 to from about amino acid 938 of SEQ ID NO: 1.

### Claim 42

(canceled)

### Claim 43 (depends on 40)

The polypeptide of claim 40, comprising from about 50 to 107 consecutive amino acids of amino acids 321-428 of SEQ ID NO: 1.

### Claim 44 (depends on 40)

The polypeptide of claim 40, comprising a derivative of the portion of the LANA1 central repeat domain having five or more iterations of one or both of the amino acid sequences DEED (SEQ ID NO: 8) and DEEE (SEQ ID NO: 9).

### Claim 45 (depends on 40)

The polypeptide of claim 40, wherein the polypeptide comprises from 50 to 100 consecutive amino acids comprising at least about 95% D and E residues.

### Claim 46 (depends on 40)

The polypeptide of claim 40, further comprising at least about 25 consecutive amino acids from a GA repeat region of an EBV EBNA1 protein.

### Claim 47 (depends on 40)

An isolated nucleic acid comprising an open reading frame encoding the polypeptide of claim 40.

### Claim at position 26

48-50. (canceled)
